News

USDA approves new label indications for Elanco’s AviPro® Megan® Egg for Turkeys

Megan Egg is a safe, effective and targeted Salmonella intervention for chickens and turkeys

GREENFIELD,Ind.July13, 2016 — Elanco Animal Health announced today that the U.S. Department of Agriculture (USDA) has approved AviPro®Megan®Egg for Salmonella prevention in live turkey production.AviPro Megan Egg for turkeys is a USDA­licensed vaccine recommended as an aid in the prevention of Salmonella Typhimurium (ST) colonization of the liver and spleen.

Prior to the expanded label indications for turkeys, AviPro Megan Egg was approved for the vaccination of chickens as an aid in the reduction of Salmonella Enteritidis colonization of the internal organs, the intestinal tract and ceca.

As part of a comprehensive Salmonella control program, AviPro Megan Egg is a safe, effective and targeted Salmonella intervention ⎯and the first Salmonella vaccine to be labeled for turkeys.1,2It delivers Salmonella colonization reduction and immunity development in turkeys ⎯ultimately contributing to reduced environmental prevalence over time.2,3

With coarse­spray and drinking water applications, AviPro Megan Egg’s two dose application protocol easily adapts to most vaccine programs. For less than two cents per bird, AviPro Megan Egg provides an effective option as part of a Salmonella control program ⎯and customer brand protection.

“Prioritizing food chain, brand and bird protection with consistent, comprehensive Salmonella control programs mitigates risk from egg to end consumer,” said Dr. Brian McComb, DVM, poultry technical consultant at Elanco. “The expansion of AviPro Megan Egg in turkeys supports a proactive approach to Salmonella control, enabling companies to reduce Salmonella risk while meeting customer, regulatory and ultimately consumer demands.”

 

Research has shown Salmonella reduction in turkeys

In a controlled study, one­day old poults were vaccinated with AviPro Megan Egg, revaccinated through drinking water at three weeks of age and then challenged with wild­type Salmonella Typhimurium at seven weeks of age. Megan Egg­treated poults showed significantly reduced Salmonella colonization post­challenge compared to non­vaccinated poults.2

Vaccination has proven to be a valuable tool in a comprehensive Salmonella control program

However, vaccination alone can’t be relied upon to prevent Salmonella. A comprehensive control program requires an integrated approach, including optimizing gut health, strong biosecurity measures, environmental monitoring, litter management, pest and rodent control, and water and feed management.

Elanco is proud to add AviPro Megan Egg for turkeys to Elanco’s portfolio of proactive Salmonella protection solutions for the poultry industry. Contact Elanco's poultry team to learn more about solutions for your comprehensive control program.

 

VisitElanco.us/Meganformoreinformation.

 

About Elanco

Elanco provides comprehensive products and knowledge services to improve animal health and food­animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human­animal bond. Founded in

1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com

 

 

Important Safety Information

Warning: Do not vaccinate within 21 days before slaughter. Contact Elanco with questions or concerns at 1­800­428­4441 or 1­

888­545­5973.

 

This press release contains forward­looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about AviPro® Megan® Egg for Salmonella prevention in live turkey production, and reflects Lilly/Elanco's current belief. However, as with any animal health product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that AviPro® Megan® Egg will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10­K and Form 10­Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward­looking statements to reflect events after the date of this release.

 

The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions.

This vaccine is recommended for vaccination of turkeys as an aid in the prevention of Salmonella Typhimurium colonization of liver and spleen.

Administration: This vaccine is recommended for use at one day of age by coarse spray application, followed by revaccination in the drinking water at 3 weeks of age.

 

1Elanco Animal Health. Data on file.

2Elanco Animal Health. Data on file.

32015. Wooming, B., M. Morgan. AVMA/AAAP Poster: Comparison of Two Salmonella Vaccines in Commercial Tom Turkeys.

AviPro, Megan, Elanco, and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

©2016 Eli Lilly and Company, its subsidiaries or affiliates. vacc 2970­1 USPBUMUL01724